Review of sertraline in post-traumatic stress disorder

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 10, 2002, Pages 1489-1499

  Schwartz, Ann C ^a   Rothbaum, Barbara O ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Clinical efficacy; Post traumatic stress disorder; Serotonin re uptake inhibitors; Sertraline; Tolerability

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG OVERDOSE; DRUG STRUCTURE; DRUG TOLERABILITY; EMOTIONAL STRESS; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INSOMNIA; LETHALITY; LIFE SATISFACTION; MALE; MEDICAL DECISION MAKING; MENTAL DISEASE; NAUSEA; POPULATION RESEARCH; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PSYCHOTRAUMA; QUALITY OF LIFE; RESTLESSNESS; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SOMNOLENCE; TREMOR; VERTIGO; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; RECURRENCE; SERTRALINE; STRESS DISORDERS, POST-TRAUMATIC;

EID: 0036799221     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.10.1489     Document Type: Article

References (138)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders - IV. (1994) American Psychiatric Association, Washington DC, USA
2. KESSLER RC, SONNEGA A, BROMET E, HUGHES M, NELSON CB: Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry (1995) 52:1048-1060.
3. BRESLAU N, DAVIS GC, ANDRESKI MA, PETERSON E: Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch. Gen. Psychiatry (1991) 48:216-222.
4. RESNICK HS, KILPATRICK DG, DANSKY BS, SAUNDERS BE, BEST CL: Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. J. Consul. Clin. Psychology (1993) 61:984-991.
5. DAVIDSON JR, HUGHES D, BLAZER DG, GEORGE LK: Post-traumatic stress disorder in the community: an epidemiological study. Psychological Medicine (1991) 21(3):713-721.
6. SOLOMON SD, DAVIDSON JR: Trauma: prevalence, impairment, service use, and cost. J. Clin. Psychiatry (1997) 58(Suppl. 9):5-11.
7. NORRIS FH: Epidemiology of trauma: frequency and impact of different potentially traumatic events on different demographic groups. J. Consult. Clin. Psychology (1993) 61:984-991.
8. BRADY K, PEARLSTEIN T, ASNIS GM et al.: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA (2000) 283:1837-1844.
9. MCFARLANE AC, ATCHISON M, RAFALOWICZ E, PAPAY P: Physical symptoms in post-traumatic stress disorder. J. Pychosom. Res. (1994) 38(7):715-726.
10. CORDOVA MJ, ANDRYKOWSKI MA, KENADY DE, MCGRATH PC, SLOAN DA, REDD WH: Frequency and correlates of posttraumatic-stress-disorder-like symptoms after treatment for breast cancer. J. Consult. Clin. Psychology (1995) 63(6):981-986.
11. FERRADA-NOLI M, ASBERG M, ORMSTAD K, LUNDIN T, SUNDBOM E: Suicidal behavior after severe trauma. Part 1: PTSD diagnoses, psychiatric comorbidity, and assessments of suicidal behavior. J. Trauma Stress (1998) 11(1):103-112.
12. WENNINGER K, HEIMAN JR: Relating body image to psychological and sexual functioning in child sexual abuse survivors. J. Trauma Stress (1998) 11(3):543-562.
13. RIGGS DS, BYRNE CA, WEATHERS FW, LITZ BT: The quality of the intimate relationships of male Vietnam veterans: problems associated with posttraumatic stress disorders. J. Trauma Stress (1998) 11(1):87-101.
14. BECKHAM JC, LYTLE BL, FELDMAN ME: Caregiver burden in partners of Vietnam War veterans with posttraumatic stress disorder. J. Consult. Clin. Psychology (1996) 64(5):1068-1072.
15. ROTHBAUM BO, MARSHALL R, FOA EB, LINDY J, MELLMAN L: Posttraumatic stress disorder. In: Treatment of Psychiatric Disorders. Third Edition. Gabbard GO (Ed.), American Psychiatric Press, Inc., Washington D.C., USA (2001):1539-1566.
16. CHARNEY DS, DEUTCH AY, KRYSTAL JH, SOUTHWICK SM, DAVIS M: Psychobiologic mechanisms of posttraumatic stress disorder. Arch. Gen. Med. (1993) 50(4):294-305.
17. YEHUDA R: Psychoneuroendocrinology of post-traumatic stress disorder. Psychiatr. Clin. North Am. (1998) 21(2):359-379.
18. BRAUN P, GREENBER D, DASBERG H, LERER B: Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J. Clin. Psychiatry (1990) 51:236-238.
19. FORSTER PL, SCHOENFELD FB, MARMAR CR, LANG AJ: Lithium for irritability in post-traumatic stress disorder. J. Trauma Stress (1995) 8:143-149.
20. LIPPER S, DAVIDSON JR, GRADY TA et al.: Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics (1986) 27:849-854.
21. FORD N: The use of anticonvulsants in posttraumatic stress disorder: case study and overview. J. Trauma Stress (1996) 9:857-863.
22. FESLER FA: Valproate in combat-related postrraumatic stress disorders. J. Clin. Psychiatry (1991) 52:361-364.
23. MARSHALL RD, PIERCE D: Implications of recent findings in posttraumatic stress disorder and the role of pharmacotherapy. Harvard Rev. Psychiatry (2000) 7:247-256.
24. HUDSON JI, POPE HG JR.: Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology? Am. J. Psychiatry (1990) 147(5):552-564.
25. DAVIDSON J, KUDLER H, SMITH R et al.: Treatment of post-traumatic stress disorder with amitriptyline and placebo. Arch. Gen. Psychiatry (1990) 47:259-266.
26. FRANK JB, KOSTEN TR, GILLER EF JR, DAN E: A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am. J. Psychiatry (1988) 145:1289-1291.
27. KOSTEN TR, FRANK JB, DAN E, MCDOUGLE CJ, GILLER EL JR: Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J. Nerv. Ment. Dis. (1991) 179:366-370.
28. REIST C, KAUFFMANN CD, HAIER RJ et al.: A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am. J. Psychiatry (1989) 146(4):513-516.
29. DAVIDSON JR, KUDLER HS, SAUNDERS WB et al.: Predicting response to amitriptyline in posttraumatic stress disorder. Am. J. Psychiatry (1993) 150(7):1024-1029.
30. SHESTATSKY M, GREENBERG D, LERER B: A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res. (1988) 24(2):149-155.
31. BAKER DG, DIAMOND BY, GILLETE G, HAMMER M: A double-blind, randomized, placebo-controlled, multicenter study of brofaromine in the treatment of posttraumatic stress disorder. Psychopharmacol. (1995) 122:386-389.
32. KATZ RJ, LOTT MH, ARBUS P et al.: Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety (1994-5) 1:169-174.
33. NEAL LA, SHAPLAND W, FOX C: An open trial of moclobemide in the treatment of post-traumatic stress disorder. Int. Clin. Psychopharmacol. (1997) 12:231-237.
34. FINLEY PR: Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann. Pharmacother. (1994) 28:1359-1369.
35. MCRAE AL, BRADY KT: Review of sertraline and its clinical applications in psychiatric disorders. Expert Opin. Pharmacother. (2001) 2(5):883-892.
36. DAVIS LL, ENGLISH BA, AMBROSE SM, PETTY F. Pharmacotherapy for posttraumatic stress disorder: a comprehensive review. Expert Opin. Pharmacother. (2000) 2(10):1583-1595.
37. Zoloft Package Insert (USA) Pfizer, Inc. 2002.
38. HIEMKE C, HARTTER S: Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. (2000) 85:11-28.
39. HYMAN SE, ARANA GW, ROSENBAUM JF: Antidepressant Drugs. In: Handbook of Psychiatric Drug Therapy, Third Edition. Little, Brown and Company. New York, NY, US (1995):43-92.
40. REIMHERR FW, CHOUINARD G, COHN CK et al.: Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J. Clin. Psychiatry (1990) 51(Suppl. B):18-27.
41. PRESKORN SH: Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. (1997) 32(Suppl. 1):1-21.
42. RICHELSON E: Pharmacokinetic drug interactions of new antidepressants: A review of the effects of the metabolism of other drugs. Mayo Clin. Proc. (1997) 72(9):835-847.
43. FULLER RW. Basic advances in serotonin pharmacology. J. Clin. Psychiatry (1992) 53(Suppl. 10):36-45.
44. GRIMSLEY SR, JANN MW: Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin. Pharm. (1992) 11:930-957.
45. BOLDEN-WATSON C, RICHELSON E: Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. (1993) 52:1023-1029.
46. MACQUEEN G, BORN L, STEINER M: The selective serotonin reuptake inhibitor sertraline: It's profile and use in psychiatric disorders. CNS Drug Rev. (2001) 7(1):1-24.
47. TOLLEFSON GD: Selective serotonin reuptake inhibitors. In: Textbook of Psychopharmacology. Schatzberg AF & Nemeroff CB (Eds), American Psychiatric Press, Inc., Washington, D.C. (1995):161-182.
48. WARRINGTON SJ: Clinical implications of the pharmacology of serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. (1992) 7(Suppl. 2)(12):13-19.
49. RUDORFER MV, POTTER WZ: The role of metabolites of antidepressants in the treatment of depression. CNS Drugs (1997) 7(4):273-312.
50. LEVINE B, JENKINS AJ, SMIALEK JE: Distribution of sertraline in postmortem cases. J. Anal. Toxicol. (1994) 18:272-274.
51. RONFELD RA, WILNER KD, BARIS BA. Sertraline. Chronopharmacokinetics and the effect of co-administration with food. Clin. Pharmacokinet. (1997) 32 (Suppl. 1):50-55.
52. DEVANE CL: Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell. Mol. Neurobiol. (1999) 19(4):443-466.
53. SCHWENK MH, VERGA MA, WAGNER JD: Hemodialyzability of sertraline. Clin. Nephrol. (1995) 44:121-124.
54. VAN HARTEN J: Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharacokinet. (1993) 24(3):203-220.
55. LANE RM: Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. (1996) 11(5):31-59.
56. MARTENYI F, BROWN EB, ZHANG H, PRAKASH A, KOKE SC: Fluoxetine versus placebo in posttraumatic stress disorder. J. Clin. Psychiatry (2002) 63(3):199-206.
57. CONNOR KM, SUTHERLAND SM, TUPLER LA, MALIK ML, DAVIDSON JR: Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br. J. Psychiatry (1999) 175:17-22.
58. MALIK ML, CONNOR KM, SUTHERLAND SM, SMITH RD, DAVISON RM, DAVIDSON JR. Quality of life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo-controlled trial of fluoxetine. J. Trauma Stress (1999) 12(2):387-393.
59. VAN DER KOLK BA, DREYFUSS D, MICHAELS M et al.: Fluoxetine in posttraumatic stress disorder. J. Clin. Psychiatry (1994) 55(12):517-522
60. TUCKER P, ZANINELLI R, YEHUDA R, RUGGIERO L, DILLINGHAM K, PITTS CD: Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a pacebo-controlled, flexible-dosage trial. J. Clin. Psychiatry (2001) 62(11):860-868.
61. MARSHALL RD, BEEBE KL, OLDHAM M, ZANINELLI R: The efficacy and safety of paroxetine for adults with chronic PTSD: a fixed dose, multi-center, placebo-controlled study. Am. J. Psychiatry (2001) 158(12):1982-1988.
62. DAVIDSON JR, ROTHBAUM BO, VAN DER KOLK BA, SIKES CR, FARFEL G: Multi-center, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch. Gen. Psychiatry (2001) 58(5):485-492.
63. ROTHBAUM BO, DAVIDSON JR, VAN DER KOLK B, BRADY KT, SIKES C, FARFEL G: Double-blind comparison of sertraline and placebo in patients with posttraumatic stress disorder. International Society for Traumatic Stress Studies, November, 1998, Washington, DC.
64. RAPAPORT MH, ENDICOTT J, CLARY CM: Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. J. Clin. Psychiatry (2002) 63(1): 59-65.
65. BRADY KT, SONNE SC, ROBERTS JM: Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J. Clin. Psychiatry (1995) 56(11):502-505.
66. KLINE NA, DOW BM, BROWN SA, MATLOFF JL: Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder. Presented at the 146th Annual Meeting, American Psychiatric Association, San Francisco, CA., May, 1993.
67. ROTHBAUM BO, NINAN PT, THOMAS L: Sertraline in the treatment of rape victims with Posttraumatic Stress Disorder. J. Trauma Stress (1997) 9: 879-885.
68. BRADY K, AUSTIN C: Affective and anxiety comorbidity in PTSD treatment trials of sertraline [poster] (Eng). 7th European Conference on Traumatic Stress (ESTSS), (May 26 - 29, 2001). Edinburgh, Germany.
69. Physician's Desk Reference (PDR, 2001).
70. ZOHAR J, AMITAL D, MIODOWNIK C et al.: Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J. Clin. Psychopharmacol. (2002) 22(2):190-195.
71. LONDBORG PD, HEGEL MT, GOLDSTEIN S et al.: Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J. Clin. Psychiatry (2001) 62:325-331.
72. DAVIDSON J, PEARLSTEIN T, LONDBORG P et al.: Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: Results of a 28-week double-blind, placebo-controlled study. Am. J. Psychiatry (2001) 158:1974-1981.
73. NELSON JC: Safety and tolerability of the new antidepressants. J. Clin. Psychiatry (1997) 58:26-31.
74. HADDAD P: Newer antidepressants and the discontinuation syndrome. J. Clin. Psychiatry (1997) 58:17-22.
75. HADDAD P: The SSRI discontinuation syndrome. J. Psychopharmacol. (1998) 12:305-313.
76. HADDAD P: Antidepressant Discontinuation Syndromes. Drug Saf. (2001) 24:183-197.
77. FAVA GA, GRANDI S: Withdrawal syndromes after paroxetine and sertraline discontinuation. J. Clin. Psychopharmacol (1995) 15(5):374-375.
78. FROST L, LAL S: Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors. Am. J. Psychiatry (1995) 152:810.
79. LEITER FL, NIERENBERG AA, SANDERS KM, STERN TA: Discontinuation reactions following sertraline. Biol. Psychiatry (1995) 38:694-695.
80. LOUIE AK, LANNON RA, AJARI LJ: Withdrawal reaction after sertraline discontinuation. Am. J. Psychiatry (1994) 151:450-451.
81. GOLDBERG RJ: Selective serotonin reuptake inhibitors: Infrequent medical adverse effects. Arch. Fam. Med. (1998) 7:78-84.
82. JACKSON C, CARSON W, MARKOWITZ J, MINTZER J: SIADH associated with fluoxetine and sertraline therapy. Am. J. Psychiatry (1995) 152:809-810.
83. CREWS JR, POTTS NL, SCHREIBER J, LIPPER S: Hyponatremia in a patient treated with sertraline. Am. J. Psychiatry (1993) 150:1564.
84. THORNTON S, RESCH D: SIADH associated with sertraline therapy. Am. J. Psychiatry (1995) 152:809.
85. LLORENTE M, GORELICK M, SILVERMAN M: Sertraline as the cause of inappropriate antidiuretic hormone secretions Clin. Psychiatry (1994) 22:543-544.
86. LIU BA, MITTMANN N, KNOWLES SR, SHEAR, NH: Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: A review of spontaneous reports. CAMJ (1996) 155:519-527.
87. BRADLEY ME, FOOTE EF, LEE EN, MERKLE L: Sertraline-associated syndrome of inappropriate antidiuretic hormone: Case report and reviews of the literature. Pharmacotherapy (1996) 16:680-683.
88. CATALANO G, KANFER SN, CATALANO MC, ALBERTS VA: The role of sertraline in a patient with recurrent hyponatremia. Gen. Hosp. Psychiatry (1996) 18:278-283.
89. GOLDSTEIN L, BARKER M, SEGALL F, et al.: Seizure and transient SIADH associated with sertraline. Am. J. Psychiatry (1996) 153:732.
90. LOWENTHAL MN: Sertraline-induced hyponatremia in an older patient. J. Am. Geriatr. Soc (1999) 47(10):1274.
91. RAPHAEL K, TOKESHI J: Hyponatremia associated with sertraline and fluoxetine: A case report. Hawaii Medical Journal (2002) 61(3):46-47.
92. CHOO V: Paroxetine and extrapyramidal reactions. Lancet (1993) 341:624.
93. SACHDEV P: The identification and management of drug-induced akathisia. Drugs (1995) 4:28-46.
94. GOLDSTEIN BJ, GOODNICK PJ: Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmoeconomics. J. Psychopharmocal. (1998) 12(No. 3, Suppl. B):S55-S87.
95. ALTSHULER LL, PIERRE JM, WIRSHING WC, AMES D.: Setraline and akathisia. J. Clin. Psychopharmacol. (1994) 14:278-279.
96. LAPORTA L: Sertraline-induced akathisia. J. Clin. Psychopharmacol. (1993) 13:219-220.
97. SETTLE E: Akathisia and sertraline. J. Clin. Psychiatry (1993) 54:321.
98. MENDEL J: Clinical experience with serotonin reuptake inhibiting antidepressants. J. Clin. Psychiatry (1987) 48:26-30.
99. CALHOUN JW CALHOUN DD: Prolonged bleeding time in a patient treated with sertraline. Am. J. Psychiatry (1996) 153(3):443.
100. YARYURA-TOBIAS JA, KIRSCHEN H, NINAN P, MOSBERG HJ: Fluoxetine and bleeding in obsessive-compulsive disorder. Am. J. Psychiatry (1991) 148:949.
101. ARANTH J, LINDBERG C: Bleeding, a side effect of fluoxetine. Am. J. Psychiatry (1992) 149:412.
102. GUNZBERGER DW, MARTINEZ D: Adverse vascular effects associated with fluoxetine. Am. J. Psychiatry (1992) 149:1751.
103. OTTERVANGER JP, STRICKER BHCH, HULS J, WEEDA JN: Bleeding attributed to the intake of paroxetine. Am. J. Psychiatry (1994) 151:781-782.
104. VANDEL P, VANDEL S, KANTELIP JP. SSRI-induced bleeding: two case reports. Therapie (2001) 56(4):445-447.
105. STAHL S: Platelets as pharmacologic models for the receptors and biochemistry of monoaminergic neurons in the platelets. In: Longnecker GL, ed. Physiology and Pharmacology. Orlando, FL: Academic Press (1985):307-340.
106. FISCH C & KNOEBEL SB: Electrocardiographic findings in sertraline depression trials. Drug Invest. (1992) 4:305-312.
107. SUNDERJI R, PRESS N, AMIN H, GIN K: Unstable angina associated with sertraline. Can. J. Cardiol. (1997) 13:849-851.
108. BERTI CA & DOOGAN DP: Sudden chest pain with sertraline. Lancet (1994) 343:1510-1511.
109. IRUELA LM: Sudden chest pain with sertraline. Lancet (1994) 343:1106.
110. SHELINE YI, FREEDLAND KE, CARNEY RM: How safe are serotonin reuptake inhibitors for depression in patients with coronary artery disease. Am. J. Med. (1997) 102:54-59.
111. SHAPIRO PA, LESPERANCE F, FRASURE-SMITH N et al.: An open-label preliminary of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT trials). Sertraline anti-depressant heart attack trial. Am. Heart J. (1999) 137: 1100-1106.
112. NAIR GV, GURBEL PA, O'CONNOR CM, GATTIS, WA, MURUGESAN SR, SEREBRUANY VL: Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. Am. J. Cardiol. (1999) 84(3):321-323.
113. MCFARLANE A, KAMATH MV, FALLEN EL, MALCOLM V, CHERIAN F, NORMAN G: Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am. Heart J. (2001) 142(4):617-623.
114. MUSSELMAN DL, MARZEE UM, MANATUNGA A et al.: Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch. Gen. Psychiatry. (2000) 57(9):875-882.
115. STERNBACH H: The serotonin syndrome. Am. J. Psychiatry (1991) 148:705-713.
116. OATES JA, SJOERDSMA A: Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology (1960) 10:1076-1078.
117. NIERENBERG DW, SEMPREBON M. The central nervous system serotonin syndrome. Clin. Pharmacol Ther (1993) 53:84-88.
118. NEMEROFF CB, DEVANE L, POLLOCK BG: Newer antidepressants and the Cytochrome P450 System. Am. J. Psychiatry (1996) 153:311-320.
119. PERRY CM, BENFIELD P: Sertraline.An overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs (1997) 7:480-500.
120. OZDEMIR V, NARANJO CA, HERRMANN N et al.: The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. J. Clin. Psychopharmacol. (1998) 18:55-61.
121. SPROULE BA, OTTON SV, CHEUNG SW, ZHONG XH, ROMACH MK, SELLERS EM: CYP2D6 inhibition in patients treated with sertraline. J. Clin. Psychopharmacol. (1997) 17:102-106
122. ALDERMAN J, PRESKORN SH, GREENBLATT DJ et al.: Desipramine pharmacokinetics when co-administered with paroxetine or sertraline in extensive metabolizers. J. Clin. Psychopharmacol. (1999) 17:284-291.
123. KURTZ DL, BERGSTROM RF, GOLDBERG MJ, CERIMELE BJ: The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin. Pharmacol. Ther. (1997) 62:145-156.
124. PRESKORN SH, ALDERMAN J, CHUNG M, HARRISON W, MESSIG M, HARRIS S: Pharmacokinetics of desipramise co-administered with sertraline or fluoxertine. J. Clin. Psychopharmacol. (1994) 14:90-98.
125. ZUSSMAN BD, DAVIS CC, FOWLES SE et al.: Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br. J. Clin. Pharmacol. (1995) 39:550P-551P.
126. SOLAI LK, MULSANT BH, POLLOCK BG et al.: Effect of sertraline on plasma nortriptyline levels in depressed elderly. J. Clin. Psychiatry (1997) 58:440-443.
127. PRESKORN SH: Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. J. Psychopharmacol. (1998) 12(Suppl. B):S89-S97.
128. GOODNICK PJ & GOLDSTEIN BJ: Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology. J. Psychopharmacol. (1998) 12(Suppl. B):S5-S20.
129. APSELOFF G, WILNER KD, GERBER N, TREMAINE LM: Effect of sertaline on protein binding of warfarin. Clin. Pharmacokinetics (1997) 32(Suppl. 1):137-42.
130. RAPEFORT WG, WILLIAMS SA, MUIRHEAD DC, DEWLAND PM, TANNER T, WESNES K: Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J. Clin. Psychiatry (1996) 57(Suppl. 1):20-23.
131. PINNINTI NR, DE LEON J: Interaction of sertaline with clozapine. J. Clin. Psychopharmacol. (1997) 17(2):199-220.
132. CHONG SA, TAN CH, LEE HS: Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J. Clin. Psychopharmacol. (1997) 17(1):68-69.
133. PRESKORN SH, ALDERMAN J, GREENBLATT DK, HORST WD: Sertraline does not inhibit cytochrome (P450) 3A-mediated drug metabolism in vivo. Psychopharmacol. Bull. (1997) 33:659-665.
134. CENTORRINO F, BALDESSARINI RJ, FRANKENBURG FR, KANDO J, VOLPICELLI SA, FLOOD JG: Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am. J. Psychiatry (1996) 153(6):820-822.
135. HOEHNS JD, FOUTS MM, KELLY MW, TU KB: Sudden cardiac death with clozapine and sertraline combination. Ann. Psychoparmacother. (2001) 35(7-8):862-866.
136. HAMILTON SP, NUNES EV, JANAL M, WEBER L. The effect of sertraline on methadone plasma levels in methadone-maintenance patient. AM. J. Addict. (2000) 9:63-9.
137. KAUFMAN KR, GERNER R: Lamotrigine toxicity secondary to sertraline. Seizure (1998) 7:163-165.
138. DAVIDSON JRT, LONDBROG P, PEARLSTEIN T, ROTHBAUM BO, BRADY K, FARFEL GM. Double-Blind Randomized, 28-Week Continuation Study Of Sertraline And Placebo In Posttraumatic Stress Disorder (PTSD). Presented at the American Psychiatric Association Annual Meeting, (May 13-18, 2000), Chicago, IL, US.